Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 11/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.49 |
| ▸ | KDM5A | P29375 | 5/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17621696 | 0.90 | KDM5B (0.54) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17693178 | 0.88 | KDM4C (0.53) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17621778 | 0.87 | KDM5B (0.69) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17621698 | 0.87 | KDM5B (0.53) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17695521 | 0.86 | KDM5B (0.57) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17621694 | 0.85 | KDM5B (0.57) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17621699 | 0.84 | KDM5B (0.58) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL17695493 | 0.83 | KDM5B (0.58) | KDM5BKDM4CKDM5AKDM2B | |
| SCHEMBL17693172 | 0.80 | KDM4C (0.51) | KDM5BKDM4CKDM5AKDM2BPHF8 | |
| SCHEMBL24244151 | 0.80 | KDM5B (0.55) | KDM5BKDM4CKDM5AKDM2BPHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193881-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM5B 11/4885KDM4C 14/4885KDM5A 10/4885 |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM5B 11/4885KDM4C 14/4885KDM5A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.